{"transactions":[{"id":1992294,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":116448,"kind":"person","name":"Neuman Linda L","position":1,"cik":"0001951205","reported_name":"Neuman Linda L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-24T23:25:30.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":550000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":550000,"derivative":{"exercise_price":0.44,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":550000},"source":{"system":"sec-edgar","filing":"0001209191-23-012882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000120919123012882/doc4.xml","form_type":"4"}},{"id":2043467,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":116448,"kind":"person","name":"Neuman Linda L","position":1,"cik":"0001951205","reported_name":"Neuman Linda L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-27T23:20:39.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest as to 1/4th of the total shares on November 14, 2023, and then 1/48th of the shares will vest monthly thereafter, such that the option will become fully vested on November 14, 2026, subject to the Reporting Person's provision of service to the issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.36,"expiration_date":"2032-11-13","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-005351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000120919123005351/doc4.xml","form_type":"4"}}]}